Nektar Therapeutics Announces Data from Rezpegaldesleukin Accepted for Late-Breaking Oral Abstract Presentation At ACAAI 2025 Annual Scientific Meeting
Nektar Therapeutics announced that new data from the ongoing REZOLVE-AD Phase 2b study of rezpegaldesleukin, an IL-2 pathway…